Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial-Reference-Cited by-同舟云学术

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Published:2015-02 Issue:2 Volume:16 Page:169-176
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Farooqui Mohammed Z H,Valdez Janet,Martyr Sabrina,Aue Georg,Saba Nakhle,Niemann Carsten U,Herman Sarah E M,Tian Xin,Marti Gerald,Soto Susan,Hughes Thomas E,Jones Jade,Lipsky Andrew,Pittaluga Stefania,Stetler-Stevenson Maryalice,Yuan Constance,Lee Yuh Shan,Pedersen Lone B,Geisler Christian H,Calvo Katherine R,Arthur Diane C,Maric Irina,Childs Richard,Young Neal S,Wiestner Adrian

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010

2. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion;Strati;Haematologica,2014

3. 17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach;Schnaiter;Hematol Oncol Clin North Am,2013

4. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial;Gonzalez;J Clin Oncol,2011

5. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial;Stilgenbauer;Blood,2014

Cited by 328 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Historical and Critical Assessment of Parametricism as an Architectural Style in the 21st Century;Buildings;2024-08-27

2. Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-07-10

3. Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature;Acta Haematologica;2024-02-24

4. A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter’s Transformation;Case Reports in Hematology;2024-02-24

5. Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus‐based position paper from an ad hoc expert panel;Hematological Oncology;2024-02-16